Dowling & Yahnke’s ResMed RMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
$515K Buy
2,358
+18
+0.8% +$4.1K 0.02% 275
2022
Q2
$491K Hold
2,340
0.02% 275
2022
Q1
$567K Hold
2,340
0.02% 264
2021
Q4
$610K Hold
2,340
0.03% 257
2021
Q3
$617K Sell
2,340
-127
-5% -$34.7K 0.03% 252
2021
Q2
$608K Hold
2,467
0.03% 246
2021
Q1
$479K Sell
2,467
-400
-14% -$80.2K 0.03% 252
2020
Q4
$609K Buy
2,867
+25
+0.9% +$4.99K 0.04% 233
2020
Q3
$487K Sell
2,842
-50
-2% -$9.23K 0.04% 232
2020
Q2
$555K Sell
2,892
-10
-0.3% -$1.64K 0.05% 225
2020
Q1
$427K Sell
2,902
-50
-2% -$7.96K 0.04% 228
2019
Q4
$457K Sell
2,952
-110
-4% -$15.9K 0.04% 240
2019
Q3
$414K Buy
3,062
+222
+8% +$29.1K 0.03% 243
2019
Q2
$347K Sell
2,840
-2
-0.1% -$222 0.03% 254
2019
Q1
$295K Buy
2,842
+332
+13% +$34.3K 0.03% 233
2018
Q4
$281K Hold
2,510
0.03% 223
2018
Q3
$290K Sell
2,510
-50
-2% -$5.48K 0.03% 253
2018
Q2
$265K Buy
2,560
+400
+19% +$40.5K 0.02% 255
2018
Q1
$213K Sell
2,160
-300
-12% -$28.3K 0.02% 273
2017
Q4
$208K Buy
+2,460
New +$203K 0.02% 284

Other funds holding RMD

Dowling & Yahnke's RMD Position: Q3 2022 in Review

Dowling & Yahnke increased its ResMed (RMD) stake by 0.77% in Q3 2022, buying an estimated $4.1K and bringing the position to 2,358 shares worth $515K. The position accounts for 0.02% of the portfolio, ranked #275.

Dowling & Yahnke first reported a position in RMD in Q4 2017 and has held it in 20 quarters since. The position peaked at $617K in Q3 2021. 668 funds tracked by Wall St. Rank hold RMD as of Q3 2022.

  • Dowling & Yahnke held 2,358 shares of ResMed worth $515K as of Q3 2022.
  • Dowling & Yahnke bought 18 ResMed shares in Q3 2022, an estimated $4.1K.
  • ResMed made up 0.02% of Dowling & Yahnke's portfolio in Q3 2022, its #275 holding.
  • Dowling & Yahnke first reported a position in ResMed in Q4 2017 and has held it in 20 quarters since.
  • Dowling & Yahnke's ResMed position peaked at $617K in Q3 2021.
  • 668 funds tracked by Wall St. Rank held ResMed as of Q3 2022.

Based on Dowling & Yahnke's 13F filing for Q3 2022, filed 3 Nov 2022.